Kornimate/medical-research-clean huggingface dataset:
the impact of pccm on healthcare among asthma or chronic obstructive pulmonary disease (copd) or asthma-copd overlap patients

Conditions: Asthma; COPD; Asthma-COPD Overlap

Summary: a multi-centre, retrospective study describing the impact of pccm standardized implementation on healthcare management among asthma or copd or asthma-copd overlap patients in tianjin city of china, using real world electronic medical record database collected in local health care settings.

this is a multi-center retrospective study to describe the impact of pccm on healthcare management of asthma or copd or aco patients in tianjin healthcare big data platform database in china from jan 01, 2015 to dec 31, 2020. the impact of pccm on healthcare management among asthma or copd or aco patients will be explored. analyses will be performed separately by disease, by hospitals with or without pccm implementation, by period (pre-pccm vs post-pccm period) and by hospital grade. patients enrolled into pre-pccm period who also had post-pccm visit(s) will be counted separately in two periods. the statistical analyses of this study will be primarily descriptive in nature and does not attempt to test any specific a priori hypotheses unless otherwise specified.

Eligibility criteria:
inclusion criteria: of note, the following criteria will be applied separately to the pre-pccm period and post-pccm period. * asthma: * patients were age 18 years and older. * patients had asthma diagnosis record according to the international classification of disease 10th edition (icd-10) codes j45,j45.x, j46, j46.x. * copd: * patients were age 18 years and older. * patients had copd diagnosis record according to the international classification of disease 10th edition (icd-10) codesj44 and j44.x (including the other clinical diagnostic records for copd diagnosis codes: the other clinical diagnostic records will be defined as chronic bronchitis or emphysema or chronic wheeze bronchitis+ at least one of the following prescribed medicine which will be defined as ics, laba, lama, ics/laba, laba/lama, ics/laba/lama, theophylline (sustained) , systemic glucocorticoids (iv/oral), sama, saba, saba/sama). * aco: * patients were age 18 years and older. * patients had both copd and asthma diagnosis in a single record or within one year according to the international classification of disease 10th edition (icd-10) codes j44, j44.x, j45,j45.x, j46 and j46.x. exclusion criteria: * asthma * patients with any history of diagnosis of copd. * patients had new diagnosis of copd during asthma follow up period. * copd * patients with any history of diagnosis of asthma or bronchiectasis, interstitial lung disease(i.e. pulmonary fibrosis). * patients had new diagnosis of asthma during copd follow up period. * aco • patients with any history of diagnosis of bronchiectasis, interstitial lung disease (i.e. pulmonary fibrosis).
a study of ak117 in combination with azactidine plus venetoclax in patients with acute myeloid leukemia

Conditions: ACUTE MYELOID LEUKEMIA; AML

Summary: this is a phase 1b/2 study. all patients are diagnosed with acute myeloid leukemia (aml), eastern cooperative oncology group (ecog) performance status 0-3. the purpose of this study is to evaluate the safety and efficacy of ak117 + azacitidine + venetoclax in subjects with aml.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old at the time of enrolment. * has an eastern cooperative oncology group (ecog) performance status of 0\~3, and 0\~2 are required for subjects ≥75 years old. * has a life expectancy of at least 12 weeks. * diagnosed as aml diagnosed according to who 2022 criteria. * has adequate organ function. * all female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the investigator, during and for 120 days after the last dose of study treatment. exclusion criteria: * diagnosed with acute promyelocytic leukemia, bcr-abl1-positive aml, myeloid sarcoma, mixed phenotype acute leukemia (mpal), accelerated phase or blast crisis of chronic myeloid leukemia. * has central nervous system leukemia (cnsl). * favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the national comprehensive cancer network (nccn) guidelines version 6, 2023 for aml. * previously diagnosed with another malignancy or have any evidence of residual disease. * previous allogeneic hematopoietic stem cell transplant (allo-hsct). * prior treatment with any b-cell lymphoma 2 (bcl-2) inhibitors, anti-cd47 or anti-sirpα (signal regulatory protein alpha) agent. * use strong or moderate cytochrome p450 (cyp) 3a inducers systemically within one week prior to enrollment, or currently require long-term treatment with a moderate to strong cyp3a inducer. * previously diagnosed with mds and treated with demethylating drugs. * patients with known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (new york heart association class iii or iv), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders. * other conditions where the investigator considers the patient inappropriate for enrollment.
brain activity, cognitive function, and walking ability in parkinson's disease

Conditions: Healthy Older Adults; Parkinson Disease

Summary: the dual-task automated walking performance in people with parkinson\&#39;s disease (pd) is affected by their gait disturbances and impaired executive functions. currently, the relationship between brain activity related to inhibitory control, executive functions, and dual-task walking performance in people with pd is not well understood. therefore, this study aims to investigate the significance of different executive function domains on gait stability in healthy older adults and people with pd; whether brain activation related to inhibitory control is associated with gait stability in healthy older adults and people with pd.


Eligibility criteria:
inclusion criteria: * diagnoses of idiopathic parkinson disease * stable dopaminergic medicine ≥ 2 weeks * able to walk 10 meters without aid * mini-mental status examination ≥ 24 points * no uncorrected visual or auditory disorders * education at least junior high school * no other disease may affect balance exclusion criteria: * other medical diagnoses of neurological, musculoskeletal, or cardiopulmonary disorders * history of brain surgery (e.g. deep brain stimulation)

Keywords: executive function gait electroencephalography
early versus late catheter removal in patients with acute urinary retention secondary to bph under tamsulosin treatment

Conditions: BPH With Urinary Obstruction

Summary: the aim of this work is to compare between early (3days) and late(7days) removal of urinary catheter after acute urine retention in patients with benign prostatic hyperplasia under tamsulosin treatment.

this is a prospective randomized study, men with acute urinary retention secondary to benign prostatic hyperplasia were catheterized and then, if they fulfilled the entry criteria, were randomly assigned to receive 0.4 mg tamsulosin hydrochloride for three days or seven days, after that the catheter was removed and the ability to void unaided assessed.

Eligibility criteria:
inclusion criteria: * patients having first attack of acute urinary retention secondary to bph. exclusion criteria: * renal impairment. * suspected urethral stricture. * neurogenic bladder. * cancer prostate. * medically induced retention. * previous use of alpha blockers. * history of drug hypersensitivity or allergy to tamsulosin.

Keywords: acute urinary retention bph twoc tamsulosin
oral iohexol in the management of chylous ascites after after retroperitoneal or extended lymphadenectomy

Conditions: Chylous Ascites; Abdominal Neoplasm; Pelvic Neoplasms; Retroperitoneal Lymph Node Metastasis; Retroperitoneal Lymphadenectomy; Extended Lymphadenectomy

Summary: the goal of this clinical trial is to assess the effectiveness of oral iohexol in the treatment of postoperative chylous ascites. it will also learn about the safety of oral iohexol. the main questions it aims to answer are: * confirm the potential of oral iohexol as an innovative therapeutic regimen. * confirm its ability to improve clinical outcomes for patients.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 75 years; * patients underwent retroperitoneal or extended lymphadenectomy for abdominal or pelvic malignant tumors; * patients diagnosisted with postoperative chylous ascites. chylous ascites were defined by the presence of non-infectious, milky, or creamy effluent in drainage tubes surpassing 200 ml daily, paired with triglyceride concentrations exceeding 110 mg/dl exclusion criteria: * patients with severe cardiac, hepatic and renal insufficiency; * patients with a history of iohexol allergy or allergy to contrast media; * patients who have received other interventions; * patients with severe intestinal obstruction or intestinal perforation; * patients who are unable to comply with the requirements of the study or are unable to complete follow-up.

Keywords: oral iohexol chylous ascites retroperitoneal lymphadenectomy extended lymphadenectomy abdominal malignant tumor pelvic malignant tumor
study evaluating the safety,tolerability, pk and pd of sam-531 in the subjects with mild to moderate alzheimer's disease

Conditions: Alzheimer Disease

Summary: the primary purpose of the study is to assess whether sam-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria 1. signed and dated written informed consent obtained from the subject or the subject's legally authorized representative (lar) or next of kin (if applicable), in accordance with the local regulations. the subject's caregiver must also consent to participate in the study. 2. diagnosis of probable alzheimer's disease according to national institute of neurological and communicative disorders and stroke-alzheimer's disease and related disorders association (nincds-adrda) criteria. 3. men and postmenopausal or surgically sterile women aged from 50 to 90 inclusive. postmenopausal women must have had 12 months of spontaneous amenorrhea. surgically sterile women are defined as having a hysterectomy, bilateral ovariectomy \[oophorectomy\], or bilateral tubal ligation. men who are sexually active will need to agree to use a form of contraception that is satisfactory as per the investigator. 4. able to participate in all scheduled evaluations with a high probability of completing all required procedures and neuropsychological tests. exclusion criteria 1. significant neurological disease other than alzheimer's disease, which may affect cognition (eg, epilepsy, parkinson disease). 2. current diagnosis of a major depressive disorder or other major psychiatric symptom according to the criteria of diagnostic and statistical manual of mental disorders, fourth edition text version (dsm-iv-tr). 3. current clinically significant systemic illness, which is likely to deteriorate or affect the subject's safety, influence cognitive assessment or ability to complete the study. 4. any clinically important deviation from normal limits in physical and neurological examination, vital signs, on electrocardiogram (ecg) or clinical laboratory test results that could compromise the study or be detrimental to the subject.
chemoablation for low-grade bladder cancer

Conditions: Bladder (Urothelial, Transitional Cell) Cancer

Summary: the goal of this single arm, prospective, open-label, investigator-initiated phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.

in this study, patients with histologically confirmed ta low-grade bladder cancer will undergo chemoablation with gemcitabine (six weekly instillations). the study aims to evaluate the efficacy, safety, and tolerability of chemoablation.

Eligibility criteria:
inclusion criteria: * male/female participants who are at least 18 years of age on the day of providing documented informed consent will be enrolled in this study * diagnosis of a recurrent tumor and a history of talg bca or diagnosis of primary talg bca histologically confirmed by cold cup biopsy at screening or within 8 weeks before screening * on screening cystoscopy: diameter of the largest lesion ≤15mm * number of lesions ≤5 * cystoscopy with bladder diagram including number, site, size and appearance of the tumors with photo documentation * patient who has recurrence of and not other than talg nmibc (low or intermediate eau risk) * nmibc requiring treatment with transurethral resection of bladder tumors (turbt) * negative voiding cytology for high grade (hg) disease within 8 weeks before screening * no lymph node metastasis or distant metastasis * male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment * female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment. female patients of childbearing potential must use adequate contraception during study period * willing and able to provide informed consent exclusion criteria: * tumors that clinicians suspect to be hg * positive hg cytology according to paris criteria * diameter of tumor \>15 mm * number of lesions \>5 * any previous intravesical therapy within 1 year * previous hg nmibc (within the last 3 years). it is allowed to include patients who had history of hg disease longer than 3 years ago. * past or current muscle invasive bladder cancer (i.e., t2, t3, t4) or metastatic uc * history of upper tract urothelial carcinoma (utuc) * clinically significant urethral stricture that would preclude passage of a urethral catheter * history of neurogenic bladder; active urinary retention; any other condition that would prohibit normal voiding * evidence of active urinary tract infection (uti) that in the investigator's opinion cannot be treated and resolved prior to biopsy and/or administration of study treatment * patient refused to participate * known positive human immunodeficiency virus (hiv) test. * female patients who are pregnant/breastfeeding. * female patients of childbearing potential not using adequate contraception.

Keywords: non-muscle invasive bladder cancer intravesical therapy non-surgical treatment
extensive stage sclc patients who were benefit from first-line treatment accept temozolomide maintain therapeutic

Conditions: Extensive Stage Small Cell Lung Cancer

Summary: this study evaluates temozolomide maintain therapeutic efficacy and safety in extensive stage sclc who has clinical benefit from etoposide combined los platinum (el) scheme in the first line treatment.

according to the etoposide combined los platinum (el) plan administration, every cycle was 21 days, a total of four cycle. the patients who was clinical benefit directly from el scheme in the first line treatment accept temozolomide maintenance therapy, 150mg / m2, oral d1-5. a period of 28 days, regular follow-up and evaluation of effectiveness, safety and quality of life.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 70 years old, men and women are not limited; 2. confirmed by histopathological examination sclc; 3. clinical stage for patients with extensive stage (except for the case of pleural effusion) 4. patients has no drug treatment history 5. the implementation of palliative radiotherapy for metastatic lesions, surgical treatment, after the end of treatment over 14 days. 6. there can be measured lesions (non radiation exposure site) of patients (recist) evaluation; 7. physical condition score ecog ps:0-1 8. more than expected survival time over 3 months exclusion criteria: 1. the previous platinum compounds have a history of allergies; 2. active ulcer patients; 3. patients with primary lung lesions were treated with radiotherapy; 4. chest x-ray showed clear interstitial pneumonia or patients with pulmonary fibrosis; 5. the need for treatment of brain metastases in the active phase 6. there are more serious tumor invasion, superior vena cava syndrome, or in the middle volume of malignant pleural effusion, abdominal effusion or pericardial effusion, not yet control; 7. there is a serious infection, adh abnormal secretion syndrome, poor control of diabetes,the need for the treatment of patients with severe complications such as vena cava syndrome
atrial fibrillation at the viennese university emergency department

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: the results of this study could imply that a atrial fibrillation registry, as a tool for structured diagnosis and therapy in patients with atrial fibrillation, may improve patient care for this rapidly growing population.

atrial fibrillation is the most common cardiac arrhythmia and is associated with increased cardiovascular morbidity and mortality, with stroke being an especially important and potentially devastating complication. the number of patients with atrial fibrillation is likely to increase 2.5-fold during the next 50 years, reflecting the growing proportion of elderly individuals. emergency departments play a central role in diagnosis and treatment (rhythm and rate control, initiation of anticoagulatory therapy for stroke prevention) of atrial fibrillation. additionally, embolic (e.g. stroke, mesenteric ischemia) complications of atrial fibrillation and bleeding complications (e.g. gastrointestinal and intracranial) of anticoagulatory therapy are likewise treated at emergency departments. therefor the investigators hypothesis implies that the atrial fibrillation registry could serve as a tool for structured diagnosis and therapy in patients with atrial fibrillation and therefore may improve patient care. additionally, diagnostic and therapeutic shortcomings by analyzing registry data may be detected.

Eligibility criteria:
inclusion criteria: * patients with atrial fibrillation treated at the emergency department of the medical university of vienna * signed consent exclusion criteria: * inclusion criteria not met
debridement, antibiotics and implant retention in early periprosthetic joint infection: a retrospective cohort study

Conditions: Direct Infection of Hip- and Knee Arthroplasty

Summary: introduction: periprosthetic joint infection (pji) is a common cause for reoperation after knee and hip arthroplasty surgery. debridement, antibiotics and implant retention (dair) is recommended in early infections (\< 4 weeks) and stable implants. aims: to define the success rate of dair in early infections and to identify predictors for success. material and methods: in a retrospective cohort study we included patients with hip- or knee arthroplasties reoperated for an early pji at danderyd hospital 2007-2012. logistic regression analysis was used to identify risk factors affecting success rate. primary outcome variable was the success of the dair treatment. secondary outcome variable vas risk factors for treatment failure.


Eligibility criteria:
inclusion criteria: patients treated with dair for early postoperative periprosthetic joint infection after knee- or hip arthroplasty surgery (\<4-6 weeks postoperatively) at our institution between 2007-01-01 and 2012-12-01. exclusion criteria: chronic or late presenting periprosthetic joint infection (\>6 weeks postoperatively), acute hematogenous periprosthetic joint infection, when the periprosthetic joint infection diagnosis criteria according to american musculoskeletal infection society (msis) 2011 definition of pji definitions were not fulfilled and when the initial surgical treatment was with other treatment protocol than dair including one-stage revision and two -stage revision

Keywords: joint prosthesis prosthesis-related infections joint diseases therapeutic irrigation prostheses and implants arthroplasty replacement
wheeze detection in children during dynamic bronchial situations measured by wim-pc™ recording

Conditions: Asthma, Bronchial

Summary: the wim-pc™ device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. this study was designed in order to evaluate the efficacy and safety of using the wim-pc™ device for wheeze detection during dynamic bronchial situations in infants that were hospitalized as a result of asthmatic attack.

asthma is the most common cause of hospitalization for respiratory infection in infants under one year of age. about 1-2% of infants with bronchiolitis need to be hospitalized and approximately 8% of these children require intensive care. pulmonary function tests in infants are objective, but require sedation, which is problematic in acutely ill infants. wheeze quantification by lung sounds analysis methods is objective, non invasive and has been shown to correlate with clinical status in asthma and bronchiolitis. the recording procedure is simple, requiring only the attachment of 4 ecg-size sensors to the chest wall. a 30-second recording is often adequate, but recording time can be extended as necessary, to obtain good quality data, where wheezes are detected and counted with high degree of accuracy. karmel sonix ltd has developed the wim-pc™ device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. this study was designed in order to evaluate the efficacy and safety of using the wim-pc™ device for wheeze detection during dynamic bronchial situations in infants that were hospitalized as a result of asthmatic attack.

Eligibility criteria:
inclusion criteria: * asthmatic or healthy subjects; * age up to 18 years; * subject or subject's parents/guardian is able to comprehend and give informed consent for participation in the study. exclusion criteria: * chest lesions (rush or deformity); * hemodynamic instability; * concurrent additional major illness. * concurrent participation in any other clinical study. * physician objection.

Keywords: wheeze detection
treatment protocol for the use of sorafenib in patients with advanced renal cell carcinoma

Conditions: Carcinoma, Renal Cell

Summary: this treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, bay43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. this treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. all patients in this protocol will be treated with sorafenib. in addition, data from the patients who participate in this protocol will provide additional information about the drug.


Eligibility criteria:
inclusion criteria: * patients with advanced (unresectable, recurrent or metastatic) rcc * patients reasonably likely to benefit from treatment with sorafenib as a single agent therapy * patients with an ecog performance status of 0-2 * patients who will not require other systemic anticancer therapy (except for bisphosphonates) while taking sorafenib * patients with vascular diseases such as wet macular degeneration, vasculitis, or new peptic ulcer, may be enrolled but require close monitoring in accordance with established medical practice exclusion criteria: * patients who are currently enrolled in, are eligible for, or have access to, any other sorafenib clinical trial * patients who have participated in any other sorafenib trial * patients who have had prior therapy with investigational agent(s) within the last four weeks prior to study entry * life expectancy of less than two months * patients with cardiac arrhythmias greater than grade 1 nci ctcae, version 3.0 * patients with active coronary artery disease or ischemia * patients with child-pugh class c hepatic impairment * patients with severe renal impairment or who require dialysis * patients with active uncontrolled hypertension * patients with recent or active bleeding diathesis